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SUMMARY. Genetic factors can influence the outcome of
antiviral therapy in chronic hepatitis C (HCV). We evaluated
the role of interleukin-28B single nucleotide polymorphisms
(SNPs) and inosine triphosphatase (ITPA) gene variants in
HCV cirrhosis treated with Peg-Interferon and ribavirin. A
prospective cohort of 233 patients with compensated
cirrhosis received 1–1.5 lg/kg/week of Peg-Interferon
alpha-2b plus 1000–1200 mg/day of RBV for 48 weeks. A
sustained virologic response (SVR) was achieved in 27% of
patients. On multivariate logistic analysis, the absence of
oesophageal varices (OR 3.64 CI 95% 1.27–10.44
P = 0.016), infection with genotype 2 or 3 (OR 4.06, CI
95% 1.08–15.26, P = 0.038), C/C alleles of rs12979860
SNP (OR 7.04, CI 95% 2.40–20.72, P < 0.001) and rapid
virologic response (RVR) (OR 78.29, CI 95% 16.07–381.29,
P < 0.001) were independently associated with SVR.
Patients who experienced post-treatment relapse received
lower total doses of Peg-Interferon (52.0 ± 15.8 lg/kg vs
65.7 ± 13.3 lg/kg, P < 0.001) and lower total dose of RBV
(3829 ± 1210 mg vs 4709 ± 954 mg, P < 0.001) than
patients who achieved an SVR. ITPA variants predictive of
high ITPase activity were associated with reduction of hae-
moglobin ‡3 g/dL in the first 4 weeks (P < 0.001), and with
reduction of haemoglobin <10 g/dL (P = 0.03) on treat-
ment. In conclusion, combination therapy with Peg-Inter-
feron and RBV in patients with HCV cirrhosis must be guided
by virus genotype, severity of portal hypertension, favour-
able IL-28B polymorphisms and ITPA variants, and RVR on
treatment.
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INTRODUCTION
The prevalence of hepatitis C virus (HCV) cirrhosis and the
incidence of its complications have increased recently in
several countries because of the long-term persistence of
HCV infection [1,2]. Identification and treatment of patients
with HCV cirrhosis can reduce the number of cases of
decompensation and hepatocellular carcinoma (HCC) [3–6].
There are few data on the efficacy and safety of combina-
tion therapy with Peg-Interferon (Peg-IFN) and ribavirin
(RBV), in cirrhosis with portal hypertension, because these
patients have been excluded from randomized controlled
trials. Host factors such as age, gender, staging of liver
fibrosis and steatosis, HCV genotypes, baseline HCV RNA
levels and rapid disappearance of serum HCV RNA can
influence the rate of sustained virologic response (SVR)
[7,8].
Genome-wide association studies have identified single
nucleotide polymorphisms (SNPs) located in and near the
interleukin-28B (IL-28B) locus, which encodes for IFN-k3
and is associated with a higher rate of SVR [9–11]. Two
genetic variants of rs1127354 and rs7270101 SNPs in the
inosine triphosphatase (ITPA) gene, which encode a protein
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that hydrolyses inosine triphosphate (ITP), have been found
to be associated with anaemia in patients treated with Peg-
IFN and RBV [12–14].
As patients with cirrhosis have a low SVR rate and fre-
quently have adverse events [15], it may be relevant to
identify factors associated with higher probability of viral
clearance, and to assess a patients likelihood of SVR.
We studied a large prospective cohort of patients with
compensated HCV cirrhosis to assess the safety and the
efficacy of Peg-IFN and RBV, and to evaluate the association
between virus-, genetic- and disease-related factors and SVR
and the incidence of adverse events.
PATIENTS AND METHODS
Patients selection
In this independent, investigator-driven, prospective cohort
study, we included all consecutive anti-HCV positive patients
with METAVIR stage 4 at liver biopsy and/or presence of
oesophageal varices (OV) observed at our Liver Unit between
June 2003 and June 2007. Other inclusion criteria were age
below 70 years, ultrasound scan (US) negative for focal
lesions, values of alpha-1-fetoprotein levels (AFP) £20 ng/
dL, bilirubin £2 mg/dL, albumin ‡2.8 g/dL, prothrombin
time ‡60%, alanine-aminotransferase (ALT) upper normal
limit, HCV RNA positive by polymerase chain reaction
(PCR), naı¨ve to antiviral treatment, or previously treated
with interferon alone.
Exclusion criteria were previous decompensation of cir-
rhosis, HBsAg and/or anti-HIV positivity, history of alcohol
abuse or IV drugs, platelet count £40 · 103/dL, leucocyte
count £2.0 · 103/dL or absolute neutrophil count
£1.0 · 103/dL, haemoglobin values £11 g/dL, creatinine
‡1.5 mg/dL, previous combination therapy with interferon
or Peg-IFN plus RBV. The study protocol was approved by
our hospitals Ethics Committee, and written consent was
obtained from all patients.
Baseline evaluation
At baseline, a quantitative HCV RNA was performed by
Cobas Monitor HCV v 2.0 (Roche Diagnostics, Basel, Swit-
zerland), and HCV genotyping by Innolipa (Innogenetics,
Belgium). All patients underwent clinical assessment
including haematologic control, liver function tests, renal
function tests, AFP serum levels, abdominal US and upper
gastro-intestinal endoscopy to evaluate the presence and
degree of OV.
Genetic tests
Patients were genotyped for rs12979860 SNP of the IL-28B
locus and for rs1127354 and rs7270101 SNPs of ITPA
variants using serum samples collected at baseline and fro-
zen at )80 C. DNA was purified using the QIAmp Circu-
lating Nucleic Acid Kit (Qiagen, Mainz, Germany), and DNA
samples were quantified using spectrophotometric determi-
nation. To genotype the rs12979860 SNP, we used a cus-
tom assay, while commercial genotyping assays were
available for the rs1127354 SNP (cat. C_27465000_10)
and the rs7270101 SNP (C_29168507_10). The ABI Taq-
Man allelic discrimination method commercialized by
Applied Biosystems was used, and the genotyping call was
made with SDS software v.1.3.0 (ABI Prism 7500, Foster
City, CA, USA). In accordance with previous reports [12,13],
the severity of the ITPase deficiency variable was defined
according to the allele combination of rs1127354 and
rs7270101 SNPs. The combination of two wild-type alleles
(C/C for rs1127354 SNP and A/A for rs7270101) was
predictive of absence of ITPase deficiency, while the combi-
nation with at least the presence of a minor allele (A for
rs1127354 SNP and C for rs7270101) in heterozygosis or
homozygosis form was predictive of mild, moderate or severe
ITPase deficiency.
Treatment schedules
Patients included in the cohort between June 2003 and
March 2005 received 1 lg per kilogram per body weight
weekly of Peg-IFN a2b (PEG-Intron; Schering Plough, Merck
& Co. Inc., (formerly Shering-Plough) Whitehouse Station,
NJ, USA.) plus 1000 mg/daily (patients with body weight
<70 kg) or 1200 mg/day (patients with body weight
‡70 kg) of oral RBV (Rebetol; Schering Plough) for
48 weeks. Patients included after March 2005 received
1.5 lg per kilogram per body weight weekly of Peg-IFN a2b
plus oral RBV at the same doses for 48 weeks. Granulocyte
colony-stimulating factor (G-CSF) or erythropoietin (EPO)
was used after March 2005, when Italian medical regula-
tions allowed these drugs to be used for cirrhotic patients on
combination antiviral therapy.
Clinical and virologic evaluation of therapy
All patients underwent haematologic, liver and renal func-
tion tests every 4 weeks on therapy and every 24 weeks
during post-therapy follow-up. Abdominal US control and
AFP were performed every 6 months to assess the HCC
screening and surveillance. All patients were observed for at
least 24 months. The study ended at the end of December
2009.
The primary virologic outcome was SVR, defined as
undetectable HCV RNA by sensitive qualitative PCR assay
with a cut-off <50 IU/mL (Amplicor HCV v 2.0 Roche
Diagnostics) 24 weeks after cessation of therapy. Virologic
outcomes of therapy, in accordance with European Asso-
ciation of the Study of the Liver Clinical Practice Guidelines
(8), were rapid virologic response (RVR), defined as unde-
tectable HCV RNA by PCR at 4 weeks of therapy; early
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virologic response (EVR), defined as undetectable HCV RNA
by PCR at 12 weeks of therapy; late virologic response
(LVR), defined as undetectable HCV RNA by PCR at
24 weeks of therapy; end-of-treatment virologic response
(ETR), defined as undetectable HCV RNA by PCR at
48 weeks of therapy for patients who completed entire
treatment schedule, or at the last clinical control in patients
who were withdrawn from therapy because of adverse
events. Treatment was withdrawn after 24 weeks if HCV
RNA was still positive.
Assessment of safety
Safety was assessed by haematologic control and liver
function tests, evaluation of subjective adverse events and
evidence of liver- and nonliver-related clinical events every
month during treatment. Treatment was lowered or dis-
continued if severe adverse events occurred. Before March
2005, RBV was lowered to 600 mg/day if haemoglobin
levels were lower than 10 g/dL, and was discontinued if the
values fell below 8.5 g/dL. The dose of Peg-IFN was
decreased by 50% if the total leucocyte count was
<1.5 · 103/dL or if the absolute neutrophil count
was <1.0 · 103/dL. Peg-IFN was discontinued if the total
leucocyte count dropped to <1.0 · 103/dL or the absolute
neutrophil count dropped to <0.75 · 103/dL and/or if the
platelet count fell below 25 · 103/dL. When the drugs were
stopped, they were not reintroduced.
After March 2005, when Italian medical regulations al-
lowed G-CSF and EPO for HCV cirrhotic patients on an-
tiviral combination therapy, patients with haemoglobin
levels lower than 10 g/dL were treated with alpha eryth-
ropoietin at a dose of 10 000 IU three times a week or
40 000 times a week. Patients with an absolute neutrophil
count <0.75 · 103/dL were treated with G-CSF at the dose
of 30 MU/week. RBV was lowered to 600 mg/day if hae-
moglobin levels were still lower than 10 g/dL after 4 weeks
of erythropoietin therapy, and was discontinued if the
values fell below 8.5 g/dL on erythropoietin therapy. An-
tiviral therapy was also withdrawn if ALT values exceeded
10 times upper normal limit and/or bilirubin rose beyond
4 mg/dL or if liver decompensation or HCC appeared.
To evaluate the association between the ITPase deficiency
variants and incidence of anaemia during combination
therapy, we analysed the rate of patients who experienced a
reduction of haemoglobin levels ‡3 g/dL in the first 4 weeks
of therapy or over the full course of 48 weeks, and the rate of
patients who experienced a decrease in haemoglobin to
<10 g/dL.
Statistical analysis
All data were entered into a database and analysed using
SPSS 13.0 for Windows software (SPSS Inc., Chicago, IL,
USA) on an intention-to-treat (ITT) basis. Continuous vari-
ables were expressed as mean ± standard deviation (SD) and
categorical variables as absolute and relative frequencies.
The differences between continuous data were analysed by
t-test, and corrected chi-square analysis was used for
dichotomous or categorical variables. Fishers exact test was
used to examine the association between baseline features
and SVR. Multiple logistic regression analysis was used to
identify baseline variables (age, gender, previous treatment
with interferon monotherapy, diagnosis of diabetes, presence
of OV, haemoglobin values, leucocyte and platelet counts,
AST/ALT, gamma-glutamyl transferase (GGT), bilirubin,
albumin values, prothrombin time, viral genotypes, serum
HCV RNA levels, genotypes of rs12979860 SNP, variants of
ITPA deficiency, Peg-Interferon doses and RBV doses) and on
treatment variables (RVR) associated with SVR. Variables
with a threshold value of P = 0.05 at univariate analysis
were included in the model, and variables with a threshold
value of P = 0.05 were considered significant in the final
model. The results were expressed as odds ratio (OR) and
their 95% confidence intervals (CI). Cumulative incidence
curves of haemoglobin reduction ‡3 g/L in relation to
ITPase deficiency variants were estimated with the Kaplan–
Meier method, and the differences between groups were
assessed using logrank tests.
RESULTS
Baseline clinical features
The baseline clinical features of the 233 patients included in
the cohort are shown in Table 1. One hundred and four
patients (44.6%) had OV, and 22 of them (9.4%) were on
primary prophylaxis with beta-blockers at the start of an-
tiviral therapy because they had F2 OV. Sixty-five patients
(27.9%) had a previous diagnosis of diabetes, and 75 pa-
tients (32.2%) had hypertension. Forty-eight patients
(20.6%) had values <75 · 103. The majority of patients
(85%) were infected with HCV 1b genotype, and 73.4% of
patients were naı¨ve to antiviral therapy. The prevalence of
C/C genotype of rs12979860 SNP was 29%, while the dis-
tribution of ITPA variants was the same as that described by
Thompson et al. [14,15]. One hundred and fourteen patients
received 1 lg/kg/week of Peg-IFN a2b plus 1000/1200 mg/
daily of RBV for 48 weeks, and 119 patients received
1.5 lg/kg/week of Peg-IFN a2b plus RBV at the same doses
for 48 weeks.
Virologic response
On ITT analysis, 44 patients (18.9%) achieved an RVR, 52
patients (22.3%) achieved an EVR and 19 patients (8.1%) an
LVR, with a total number of 115 patients (49.3%) who
achieved an ETR. After 24 weeks of observation from the
end of therapy, 63 patients (27.0%) achieved an SVR, while
52 patients (22.3%) showed a virologic relapse.
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Logistic regression modelling for sustained virologic
response
We analysed baseline and on-therapy variables that were
associated with SVR. On univariate analysis, absence of OV
(P = 0.016), higher albumin (P = 0.042) and ALT values
(P = 0.009), lower GGT values (P = 0.035), infection by
genotype 2 or 3 (P < 0.001), C/C genotypes of rs12979860
SNP (P < 0.001) and RVR (P < 0.001) were associated with
SVR (Table 2). On multivariate logistic analysis, absence of
OV (OR 3.64 CI 95% 1.27–10.44 P = 0.016), viral geno-
type 2 or 3 (OR 4.06, CI 95% 1.08–15.26, P = 0.038), C/C
genotype of rs12979860 SNP (OR 7.04, CI 95% 2.40–
20.72, P < 0.001) and RVR (OR 78.29, CI 95% 16.07–
381.29, P < 0.001) were independently associated with
SVR.
Viral genotypes and virologic response
Only 25 (12.5%) of 199 genotype, 1 patient achieved an
RVR vs 19 (55.9%) of 34 patients with genotype 2 or 3
(P < 0.001; Fig. 1). Rates of EVR and LVR were comparable
for different genotypes (22.1% and 8.5% for genotype 1 and
23.5% and 5.9% for genotype 2 or 3, respectively). ETR was
achieved in 86 patients (43.2%) with genotype 1, and in 29
patients (85.3%) with genotype 2 or 3 (P < 0.001). After the
end of therapy, we observed a virologic relapse in 46 of 86
genotype 1 patients (53.5%) with ETR, but in only 6 of 29
genotype 2 or 3 patients (20.1%). Overall, 40 of 199
genotype 1 patients (20.1%) and 23 of 34 patients (67.6%)
with genotype 2 or 3 achieved an SVR (P < 0.001).
Oesophageal varices and virologic response
Patients with and without OV achieved a comparable rate of
virologic response on therapy. Patients with OV had a higher
rate of relapse and, finally, the rate of SVR was significantly
higher in patients without OV than in patients with OV
(33.3% vs 19.2%, P = 0.01).
Time of virologic response on therapy and sustained
virologic response
An RVR occurred in 25 of 199 genotype 1 patients, and in
19 of 34 genotype 2 or 3 patients (12.5% vs 55.9%,
P < 0.001), while an EVR occurred in 44 of 199 genotype 1
patients, and in 8 of 34 genotype 2 or 3 patients (22.1% vs
23.5%, P = 0.6; Fig. 2). The rate of SVR was very high
regardless of genotype in patients who achieved an RVR
(92% in 25 genotype 1 patients and 84.2% in 19 genotype 2
or 3 patients), while it was correlated with genotype in
patients who achieved an EVR (34.1% in 44 genotype 1 pa-
tients and 87.5% in 8 genotype 2 or 3 patients, P = 0.007).
IL-28B polymorphisms and virologic response
Polymorphism in the interleukin-28B was available in 206
patients (88.4%; Fig. 3). In the entire cohort, the C/C
genotype of rs12979860 SNP was significantly associated
with the rate of SVR (51.6% in C/C patients vs 19.2% in C/T
or T/T patients, P < 0 .001). The rs12979860 SNP was not
a determinant of SVR in genotype 1 patients who achieved
Table 1 Clinical, virologic and genetic features of the 233
patients
Gender
Male 149 (64%)
Female 84 (36%)
Mean age
Male 57.3 ± 9.6
Female 60.1 ± 6.7
Body weight (kg, mean, SD)
Male 78.0 ± 12.9
Female 68.2 ± 13.4
Concomitant diseases
Diabetes 65 (27.9%)
Hypertension 75 (32.2%)
Oesophageal varices
Absent 129 (55.4%)
Present 104 (44.6%)
Child-pugh class
A5 183 (78.5%)
A6 46 (19.7%)
B7 4 (1.7%)
Antiviral therapy
Naı¨ve patients 171 (73.4%)
Previously treated with IFN-alone 62 (26.7%)
HCV genotypes
1 199 (85.4%)
2 or 3 34 (14.6%)
Serum HCV RNA (Log10, median, range) 6.2 (2.1–8.1)
rs12979860 SNP genotypes*
C/C 60 (29.1%)
T/C or T/T 146 (70.9%)
Predicted ITPase deficiency*
Absent 133 (64.5%)
Mild 41 (17.6%)
Moderate/severe 32 (13.7%)
ALT (UI/mL, mean ± SD,
normal values <40)
140.2 ± 88.7
GGT (UI/mL, mean ± SD,
normal values <35)
112.5 ± 64.6
Bilirubin (mg/mL, mean ± SD) 1.0 ± 0.5
Albumin (g/mL, mean ± SD) 4.0 ± 04
Prothrombin time (%, mean ± SD) 86.7 ± 15.1
Haemoglobin (g/L, mean ± SD) 14.5 ± 1.3
Leucocytes (1 · 103, mean ± SD) 5.7 ± 1.8
Platelets (10 · 103, mean ± SD) 120 ± 47.7
ALT, alpha-1-fetoprotein levels; GGT, gamma-glutamyl
transferase. *Evaluated in 206 patients.
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RVR (100% in 14 patients with C/C genotype and 87.5% in
8 patients with C/T or T/T genotype) but was a determinant
in patients who achieved EVR (59% in 17 patients with C/C
genotype and 19.2% in 26 patients with C/T or T/T geno-
type, P = 0.01).
Drugs doses and sustained virologic response
We evaluated Peg-IFN and RBV doses received by 115 pa-
tients who achieved an ETR. Higher total doses of Peg-IFN
and RBV reduced the rate of post-treatment relapse. In fact,
patients who experienced post-treatment relapse received
lower total doses of Peg-IFN (52.0 ± 15.8 lg/kg vs
65.7 ± 13.3 lg/kg, P < 0.001) and lower total dose of RBV
(3829 ± 1210 mg vs 4709 ± 954 mg, P < 0.001) than
patients who achieved an SVR. When we evaluated only
genotype 1 patients with ETR, the total dose of Peg-IFN
(52.0 ± 15.8 lg/kg vs 65.7 ± 13.3 lg/kg, P < 0.001) and
RBV (3829 ± 1210 mg vs 4709 ± 954 mg, P < 0.001)
remained significantly lower in patients who experienced
relapse than in patients who achieved an SVR.
Adverse events on therapy
Fifty-six patients (24%) were withdrawn from treatment
because of adverse events (Table S1). Twenty-one patients
Table 2 Baseline and on-therapy variables associated with SVR by univariate and multivariate analysis
No SVR (170 patients) SVR (63 patients) P OR (CI 95%) P
Age (SD) 58.9 ± 8.5 56.8 ± 9.5 0.100 –
Gender (% males) 63 66 0.599 –
Body weight (kg/m2, SD)
Male 77.7 ± 13.5 79.1 ± 11.9 0.888 –
Female 69.3 ± 12.8 64.7 ± 14.7 0.085 –
Oesophageal varices (%)
Absent 50.5 68.3 0.016 3.64 (1.27–10.44) 0.016
Present 49.5 31.7
Previous IFN therapy
Yes 25.3 30.1 0.455 –
No 74.7 69.9
Haemoglobin (g/dL) 14.5 ± 1.4 14.5 ± 1.2 0.965 –
Leucocytes (1 · 103) 5.6 ± 1.8 5.9 ± 1.8 0.266 –
Platelets (10 · 103) 118 ± 46 127 ± 48 0.104 –
Albumin (g/dL) 4.0 ± 0.4 4.1 ± 0.5 0.042 1.04 (0.42–2.42) 0.435
Bilirubin (mg/dL) 1.0 ± 0.6 0.9 ± 0.3 0.106 –
AP (%) 86 ± 16 89 ± 14 0.234 –
ALT (IU/mL) 132 ± 72 172 ± 108 0.009 1.05 (0.82–1.35) 0.687
GGT (IU/mL) 84 ± 59 66 ± 49 0.035 0.85 (0.60–1.21) 0.379
Genotype (%)
1 93.5 63.5 <0.001 3.43 (0.94–12.56) 0.061
2/3 6.5 36.5
HCV RNA (Log10) 6.01 6.21 0.232 –
Diabetes (%) 28.8 25.4 0.604 –
IL-28B (%)*
C/C 19.7 52.5 <0.001 5.71 (2.08–15.70) 0.001
C/T or T/T 80.3 47.5
ITPase deficiency variants (%)*
No deficiency 65.3 62.6 0.748
Mild deficiency 20.4 18.7
Moderate/severe deficiency 14.3 18.7
RVR (%)
Yes 3 62 <0.001 62.87 (14.16–279.08) <0.001
No 97 38
ALT, alpha-1-fetoprotein levels; GGT, gamma-glutamyl transferase; RVR, rapid virologic response; SVR, sustained virologic
response. *Evaluated in 206 patients. p values results £ 0.05 by multivariate analysis are signed in bold.
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(9.1%) stopped treatment because of specific events, with the
most common event being severe fatigue. Eight patients
(3.5%) discontinued treatment because of psychiatric or
neurologic disorders, two patients (0.8%) because of vascu-
lar disorders and three patients (1.3%) contracted serious
infection. Eight patients (3.4%) discontinued treatment
because of liver-related complications: four developed ascites,
on developed encephalopathy and one portal thrombosis. All
of them had OV. One patient showed HCC at US control after
6 months of therapy, and another patient developed an ALT
flare after 4 months of therapy. The laboratory abnormali-
ties that caused treatment discontinuation were severe
anaemia in seven patients (3%) and severe leukopenia in five
patients (2.2%), while only two patients (0.8%) had severe
thrombocytopenia.
Variants in the inosine triphosphatase gene and haemolytic
anaemia
On treatment, 105 of 133 patients (78.9%) who carried
variants predictive of high ITPase activity, 24 of 41 patients
(58%) who carried polymorphisms associated with mild
reduction in ITPase activity, and 16 of 32 patients (50%) who
carried polymorphisms associated with moderate or severe
reduction in ITPase activity experienced a reduction of hae-
moglobin levels ‡3 g/dL (P < 0.001 by logrank test; Fig. 4).
Thirty of 133 of patients (22.5%) with high ITPase activity,
but none of 41 patients withmild reduction in ITPase activity,
and only one of 32 patients (3.1%) with a moderate or severe
reduction in ITPase activity experienced a reduction of hae-
moglobin levels ‡3 g/dL in the first 4 weeks of treatment
(P < 0.001). Finally, patients with high ITPase activity had a
significantly higher risk of reduction of haemoglobin values to
<10 g/dL than patients with mild, moderate or severe
reduction in ITPase activity (51/133 vs 17/73, P = 0.03).
Among 71 patients who experienced a reduction of hae-
moglobin values to <10 g/dL, 44 patients used EPO as
support therapy and 27 adjusted RBV doses. Eighteen of 44
patients (41%) who used EPO achieved an SVR, while five of
27 patients (18.5%) who reduced RBV doses achieved an
SVR (P = 0.06).
DISCUSSION
The efficacy of antiviral therapy with Peg-IFN and RBV is
evidence based in patients with cirrhosis, as the eradication
of HCV significantly reduces the incidence of disease com-
plications and increases survival [4–6]. In this setting of
patients, the overall rate of SVR is <30%, with a clear dif-
ference between genotype 1 or 4 patients who achieved an
SVR in <20% of cases, and genotype 2 or 3 patients who
achieved an SVR in more than 50% of cases [16–18]. In
addition, the rate of therapy withdrawal because of adverse
events was higher in patients with cirrhosis than in those
with chronic hepatitis [15].
This is the first study to evaluate viral factors, genetic
variants, disease features, drugs doses and kinetics of virologic
responses that are associated with antiviral therapy outcomes
in patients with advanced, but not decompensated, cirrhosis.
About half of the patients included in our cohort had OV
and 20% had platelet counts <75 · 103. As reported by the
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studies of the HALT-C Trial Group, patients with these
characteristics have a low probability of achieving an SVR
[19] and a high probability of developing or increasing OV
[20] and of developing HCC [21] during the follow-up. In
this setting of difficult to treat patients, it is crucial to
identify predictors of SVR and host factors associated with
the development of severe adverse events on therapy and to
understand the kinetics of virologic response to apply a
response-guided strategy [8].
The overall rate of SVR in our study was 27%, with no
significant differences among the patients in terms of age,
gender and BMI. SVR was similar in naı¨ve patients and
patients previously treated with interferon alone. By
contrast, absence of OV, easy viral genotypes, favourable
IL-28B polymorphisms and RVR on therapy were all inde-
pendently associated with SVR. Patients with OV achieved
the same rate of virologic response on therapy as patients
without OV, but they had a higher rate of relapse, and
therefore, the rate of SVR was significantly higher in patients
without OV. It is difficult to explain the mechanisms
underlying these data, but it is likely that the progression of
fibrosis simultaneously increases the portal pressure and
reduces the possibility of HCV clearance [22].
The rate of SVR was 68% in genotype 2 patients, and 66%
in genotype 3 patients. In this subset of patients, the success
of therapy was not related to IL-28B polymorphisms and not
conditioned by RVR. It is unclear whether these patients
require 48 weeks of therapy or could be treated with a cycle
of 24 weeks. A recent study [18] suggests that treatment
failure was the consequence of higher rates of post-treatment
relapse in genotype 2 or 3 cirrhotic patients than in patients
with chronic hepatitis treated for 24 weeks and reported a
rate of 29% and 61% in genotype 2 and genotype 3 cirrhotic
patients, respectively. In our study, all patients were treated
for 48 weeks, and the rate of post-treatment relapse was
19% in genotype 2 patients, and 25% in genotype 3 patients.
These data reinforce the indication for PEG-IFN and RBV in
genotype 2 and 3 patients with compensated cirrhosis and
confirm the suggestion that this group of patients may
benefit from extended duration of treatment [23].
Only 20.1% of genotype 1 patients achieved an SVR, and
this low rate of success was related to IL-28B polymorphisms
and the time of virologic response during treatment. First, the
low rate of SVR may be related to low prevalence of C/C
genotype of rs12979860 SNP among genotype 1 cirrhotics,
and to the low rate of RVR. Second, we observed a high post-
treatment relapse rate in patients who carried a C/T or TT of
rs12979860 SNP and who achieved EVR or LVR. This sug-
gests that genotype 1 patients who carry C/C genotypes of
rs12979860 SNP and achieve an RVR have a very high
likelihood of achieving an SVRwith 48 weeks of combination
therapy, but patients with C/T or TT genotypes of
rs12979860 SNPwho do not achieve anRVRhave a very low
likelihood of obtaining clearance of HCV and should be con-
sidered for new therapieswith direct-acting antivirals [24,25].
Finally, we observed that the rate of SVR in the 115 patients
who achieved an ETR was related to higher doses of Peg-IFN
and RBV. Analysis of the SVR rate in patients with a virologic
response showed that patients who experienced post-treat-
ment relapse received lower doses of Peg-IFN and Ribavirin
than patients who achieved an SVR. This observation
strengthens the hypothesis that the intensification of treat-
ment is a possible approach to reducing the incidence of re-
lapse [26].
Regarding the safety of therapy, we observed that types and
frequencies of adverse events were different from those
reported in a larger randomized trial [26]. Twenty-four per
cent of our patients stopped therapy because of severe adverse
events, and we observed some events that were related to cir-
rhosis. All patientswho experienced serious infection and liver
decompensation had OV, a low platelet count and increased
bilirubin levels. As these clinical features predict liver decom-
pensation [27], and infections in patients with cirrhosis in-
crease mortality [28], the choice of antiviral therapy in these
patients must be carefully evaluated and weighed. The rate of
patients whose haemoglobin values had reduced to <10 g/dL
was similar to that reported in a previous study [26], and the
use of EPO seems to influence the efficacy of therapy because it
allows maintenance of the standard regimen of RBV.
In conclusion, our study confirms that combination
therapy with Peg-Interferon and RBV is effective and safe in
patients with cirrhosis and portal hypertension, but that
before applying it, one must consider the clinical and genetic
characteristics of patients, the viral genotypes and the
kinetics of viral response. In genotype 2 or 3 patients, the
administration of combination therapy for 48 weeks can
Fig. 4 Incidence of haemoglobin reduction ‡3 g/L during
treatment according to ITPase deficiency variants identified
by Kaplan–Meier method (P < 0.001 by logrank test).
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achieve results similar to those obtained in patients with
chronic hepatitis. In genotype 1 patients, the therapy must
be guided by the presence of OV, genetic variants and by
RVR. It is also worth noting that patients with severe portal
hypertension may have an increased risk of developing
complications related to liver disease during treatment.
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